Vivus Phase III With Alprostadil Aiming At 'Huge' FSAD Market

For reasons that might be as much socio-economic as medical, female sexual arousal disorder (FSAD) has been overlooked in favor of the lucrative market for erectile dysfunction therapies such as the pioneering phosphodiesterase type-5 inhibitor Viagra from Pfizer Inc.